scispace - formally typeset
Journal ArticleDOI

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, +12 more
- 04 Jun 2009 - 
- Vol. 113, Iss: 23, pp 5720-5726
Reads0
Chats0
TLDR
Plerixafor and G- CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone.
About: 
This article is published in Blood.The article was published on 2009-06-04. It has received 693 citations till now. The article focuses on the topics: Plerixafor & Autologous stem-cell transplantation.

read more

Citations
More filters
Journal ArticleDOI

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

Beverly A. Teicher, +1 more
- 01 Jun 2010 - 
TL;DR: This work has shown that the CXCL12/CXCR4 axis is involved in tumor progression, angiogenesis, metastasis, and survival, and this pathway is a target for therapeutics that can block the CZC receptor 4 interaction or inhibit downstream intracellular signaling.
Journal ArticleDOI

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Thomas J. Smith, +13 more
- 13 Jul 2015 - 
TL;DR: Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Book ChapterDOI

The intricate role of CXCR4 in cancer.

Samit Chatterjee, +2 more
- 01 Jan 2014 - 
TL;DR: This review provides a comprehensive overview of the biological involvement of CXCR4 in human cancers, the current status of C XCR4-based therapeutic approaches, as well as recent advances in noninvasive imaging of CxCR4 expression.
Journal ArticleDOI

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Geoffrey L. Uy, +12 more
- 26 Apr 2012 - 
TL;DR: It is concluded that the addition of plerixafor to cytotoxic chemotherapy is feasible in AML, and results in encouraging rates of remission with correlative studies demonstrating in vivo evidence of disruption of the CXCR4/CXCL12 axis.
Journal ArticleDOI

Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

Sergio Giralt, +17 more
- 01 Mar 2014 - 
TL;DR: A panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell mobilization and transplantation and to devise guidelines to optimize mobilization strategies.
References
More filters
Journal ArticleDOI

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Michel Attal, +11 more
- 11 Jul 1996 - 
TL;DR: The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Journal ArticleDOI

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

J. Anthony Child, +8 more
- 08 May 2003 - 
TL;DR: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age and trend toward a greater survival benefit in the group of patients with a poor prognosis.
Journal ArticleDOI

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Hal E. Broxmeyer, +13 more
- 18 Apr 2005 - 
TL;DR: Results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization.
Journal ArticleDOI

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Michel Attal, +13 more
- 25 Dec 2003 - 
TL;DR: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Journal ArticleDOI

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

Bart Barlogie, +20 more
- 01 Jan 1999 - 
TL;DR: Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and beta-2-microglobulin.
Related Papers (5)

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

John F. DiPersio, +9 more
- 01 Oct 2009 - 

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Neal Flomenberg, +8 more
- 01 Sep 2005 - 

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Hal E. Broxmeyer, +13 more
- 18 Apr 2005 - 

Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

W. Conrad Liles, +20 more
- 15 Oct 2003 - 

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.

Shaji Kumar, +10 more
- 21 Jun 2007 -